Background Improvement in vascular endothelial function is widely cited as a beneficial effect of hormone replacement therapy (HRT). Women with type 2 diabetes (T2DM) are at increased cardiovascular risk and have impaired endothelial function. Any benefits of HRT on endothelial function in this group are of particular interest.
Objectives We assessed effects on vascular function of oral 17β oestradiol (1 mg) and norethisterone (0.5 mg) in postmenopausal women with T2DM.
Assessments Twenty-eight women had pulse wave velocity (PWV) and adhesion molecules VCAM-1 and ICAM-1 assessed before and after three months' treatment. Twenty-four women also had gluteal fat biopsy for assessment of resistance vessel function (using wire myography).
Results HRT did not affect PWV, VCAM-1, ICAM-1 or carbachol response. Effects of L-NAME and indomethacin on carbachol sensitivity were similar in both groups.
Conclusions This HRT preparation had no detectable effect on these measures of endothelial function in women with T2DM.
1. Vallance P.Nitric oxide in the human cardiovascular system. Br J Clin Pharmacol1998;45:433–9.
2.
2. McVeigh GE, Brennan GM, Johnston GD et al.Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia1992;35:771–6.
3.
3. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA.Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol1996;27:567–74.
4.
4. Enderle MD, Benda N, Schmuelling RM, Haering HU, Pfohl M.Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects [comment]. Diabetes Care1998;21:271–7.
5.
5. Gazis A, White DJ, Page SR, Cockcroft JR.Effect of oral vitamin E (alpha-tocopherol) supplementation on vascular endothelial function in Type 2 diabetes mellitus. Diabetic Med1999;16:304–11.
6.
6. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H.Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol2000;20:545–50.
7.
7. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL.Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA1991;265:627–31.
8.
8. Mercuro G, Longu G, Zoncu S, Cherchi A.Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women. Am Heart J1999;137:692–7.
9.
9. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, Sessa WC, Bender JR.17–estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res1997;81:885–92.
10.
10. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW.Estrogen receptor (alpha) mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest1999;103:401–06.
11.
11. Darkow DJ, Lu L, White RE.Estrogen relaxation of coronary artery smooth muscle is mediated by nitric oxide and cGMP. Am J Physiol1997;272:H2765–H2773.
12.
12. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I.Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun1999;263:257–62.
13.
13. Mendelsohn ME.Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?. Circ Res2000;87:956–60.
14.
14. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G.17-beta-oestradiol-induced vasorelaxation in vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol2002;135:1695–700.
15.
15. Mercuro G, Vitale C, Fini M, Zoncu S, Leonardo F, Rosano GM.Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial. Internat J Cardiol2003;89:257–65.
16.
16. Ossewaarde ME, Bots ML, van der Schouw YT et al.Does the beneficial effect of HRT on endothelial function depend on lipid changes?. Maturitas2003;45(1):7–54.
17.
17. Gambacciani M, Monteleone P, Vitale C et al.Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. Maturitas2002;43:117–23.
18.
18. Sanada M, Higashi Y, Nakagawa K et al.A comparison of low-dose and standard-dose oral estrogen on forearm endothelial function in early postmenopausal women. J Clin Endocrinol Metab2003;88:1303–09.
19.
19. Guzic-Salobir B, Keber I, Seljeflot I, Arnesen H, Vrabic L.Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women. J Intern Med2001;250:508–15.
20.
20. Lim SC, Caballero AE, Arora S et al.The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J Clin Endocrinol Metab1999;84:4159–64.
21.
21. Perera M, Sattar N, Petrie JR et al.The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. J Clin Endocrinol Metab2001;86:1140–3.
22.
22. Koh KK, Kang MH, Jin DK et al.Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol2001;38:1409–15.
23.
23. Hulley S, Grady D, Bush T et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA1998;280:605–13.
24.
24. Writing Group for the Women's Health Initiative Investigators.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33.
25.
25. Furberg CD, Vittinghoff E, Davidson M et al.Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.[comment]. Circulation2002;105:917–22.
26.
26. Manson JE, Hsia J, Johnson KC et al.Estrogen plus Progestin and the risk of coronary heart disease. N Engl J Med2003;349:523–34.
27.
27. Herrington DM, Howard TD.From presumed benefit to potential harm–hormone therapy and heart disease.[comment]. New Engl J Med2003;349:519–21.
28.
28. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV.Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry, 1995–1998. Circulation2003;107:43–8.
29.
29. Kelly JG, Spiers A, Gould GW, Petrie JR, Lyall H, Connell JMC.Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab2002;87:742–6.
30.
30. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG.Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation2002;106:2085–90.
31.
31. Padmanabhan N, Jardine AG, McGrath JC, Connell JM.Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation1999;99:2914–20.
32.
32. Staessen JA, van der Heijden-Spek JJ et al.Menopause and the characteristics of the large arteries in a population study. J Hum Hypertens2001;15:511–18.
33.
33. Samaras K, Hayward CS, Sullivan D, Kelly RP, Campbell LV.Effects of postmenopausal hormone replacement therapy on central abdominal fat, glycemic control, lipid metabolism, and vascular factors in type 2 diabetes: a prospective study. Diabetes Care1999;22:1401–07.
34.
34. Mares P, Dauzat M, Abramovici Y.Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance. Maturitas2002;42(1):45–53.
35.
35. Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP.A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. Clin Endocrinol2001;55:673–82.
36.
36. Hillier C, Petrie MC, Love MP, Johnston F, MacLean MR, McMurray JJ.Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clin Sci2001;101(1):45–51.
37.
37. Perera M, Petrie JR, Hillier C, Small M, Connell JMC, Lumsden MA.Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. Human Reproduction2002;17:497–502.
38.
38. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C.Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden.[erratum appears in BMJ 2003;327:1381]. BMJ1999;319:890–3.
39.
39. Schofield I, Malik R, Izzard A, Austin C, Heagerty A.Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation2002;106:3037–43.
40.
40. Fegan PG, Tooke JE, Gooding KM, Tullett JM, MacLeod KM, Shore AC.Capillary pressure in subjects with type 2 diabetes and hypertension and the effect of antihypertensive therapy. Hypertens2003;41:1111–17.
41.
41. McNeish AJ, Wilson WS, Martin WDominant role of an endothelium-derived hyperpolarizing factor (EDHF)-like vasodilator in the ciliary vascular bed of the bovine isolated perfused eye. Br J Pharmacol2001;134:912–20.
42.
42. Blumel JE, Castelo-Branco C, Leal T et al.Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease. Climacteric2003;6(1):38–44.
43.
43. Squadrito F, Altavilla D, Crisafulli A et al.Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med2003;114:470–6.
44.
44. Hisamoto K, Ohmichi M, Kanda Y et al.Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem2001;276:47642–9.
45.
45. Sugden PH, Clerk A.Akt like a woman: gender differences in susceptibility to cardiovascular disease. Circ Res2001;88:975–7.
46.
46. Mendelsohn ME, Karas RH.The protective effects of estrogen on the cardiovascular system. N Engl J Med1999;340:1801–11.
47.
47. Haynes MP, Sinha D, Russell KS et al.Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res2000;87:677–82.
48.
48. Saltiel AR.Putting the brakes on insulin signaling. N Engl J Med2003;349:2560–2.
49.
49. Du K, Herzig S, Kulkarni RN, Montminy M.TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science2003;300:1574–7.
50.
50. Cushman M, Legault C, Barrett-Connor E et al.Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation1999;100:717–22.
51.
51. Berliner JA, Navab M, Fogelman AM et al.Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation1995;91:2488–96.
52.
52. Cybulsky MI, Iiyama K, Li H et al.A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Investig2001;107:1255–62.
53.
53. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD.Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. Diabetic Med2002;19:847–52.
54.
54. Goudev A, Georgiev DB, Koycheva N, Manasiev N, Kyurkchiev S.Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas2002;43(1):49–53.
55.
55. Silvestri A, Gebara O, Vitale C et al.Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation2003;107:3165–9.
56.
56. Stork S, von Schacky C, Angerer P.The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled. trial. Atherosclerosis2002;165:301–07.
57.
57. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T.Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation2002;105:1436–9.
58.
58. Seljeflot I, Arnesen H, Hofstad AE, Os I.Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease. Thromb Haemostas2000;83:944–8.
59.
59. Scarabin PY, Alhenc-Gelas M, Oger E, Plu-Bureau. Hormone replacement therapy and circulating ICAM-1 in postmenopausal women–a randomised controlled trial. Thromb Haemostas1999;81:673–5.
60.
60. Koh KK, Jin DK, Yang SH et al.Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation2001;103:1961–6.
61.
61. Zimmerman GA, McIntyre TM, Prescott SM.Adhesion and signaling in vascular cell-cell interactions. J Clin Invest1997;100(11: Suppl): Suppl-5.
